Table 3.
Neuropsychometric Tests, SF-36 Scores and Laboratory Pparameters at Baseline and after 12-week of Therapy in Both Groups
| Zinc Group | Placebo Group | P3 | |||||
|---|---|---|---|---|---|---|---|
| Baseline | 12 Weeks | P1 | Baseline | 12 Weeks | P2 | ||
| mean ± SD | mean ± SD | mean ± SD | mean ± SD | ||||
| NCT-A, sec | 64.71 ± 19.2 | 62.76 ± 17.3 | 0.132 | 71.5 ± 43.3 | 75.38 ± 42.4 | 0.113 | 0.029* |
| NCT-B, sec | 152.91 ± 44.7 | 148.53 ± 38.8 | 0.343 | 136.68 ± 53.0 | 150.87 ± 51.7 | <0.001* | 0.008* |
| SDT, sec | 113.97 ± 30.5 | 108.32 ± 29.6 | 0.003* | 105.12 ± 26.6 | 110.41 ± 29.8 | 0.104 | 0.002* |
| LTT, sec | 190.6 ± 44.2 | 188.24 ± 41.4 | 0.436 | 168.12 ± 47.6 | 164.63 ± 39.4 | 0.154 | 0.855 |
| DST, sec | 18.74 ± 6.4 | 20.5 ± 6.3 | 0.011* | 20.82 ± 8.8 | 19.09 ± 7.4 | 0.011 | <0.001* |
| PF | 65.86 ± 12.5 | 71.62 ± 9.9 | 0.004* | 65.56 ± 16.9 | 63.19 ± 18.5 | 0.515 | 0.013* |
| SF | 77.63 ± 18.8 | 86.79 ± 16.3 | <0.001* | 78.88 ± 20.9 | 79.28 ± 23.4 | 0.669 | 0.017* |
| MH | 65.6 ± 16.2 | 68.94 ± 12.2 | 0.041 | 69.53 ± 17.8 | 67 ± 17.8 | 0.154 | 0.014* |
| BP | 59.83 ± 18.8 | 68.79 ± 16.4 | 0.002 | 63.85 ± 26.8 | 65.72 ± 22.3 | 0.319 | 0.074 |
| PH | 52.43 ± 20.1 | 59.71 ± 18.1 | 0.001 | 51.62 ± 18.4 | 50 ± 20.8 | 0.709 | 0.018* |
| RP | 57.86 ± 40.1 | 63.97 ± 37 | 0.13 | 54.41 ± 42.4 | 50.78 ± 40.4 | 0.374 | 0.096 |
| RM | 52.17 ± 37.5 | 70.59 ± 36.5 | 0.002 | 52.94 ± 45.1 | 59.41 ± 41.3 | 0.13 | 0.047* |
| VT | 57.94 ± 16.2 | 63.09 ± 13.2 | 0.021 | 58.24 ± 18.9 | 58.75 ± 19.3 | 0.802 | 0.085 |
| SF-36 | 489.31 ± 125.4 | 553.5 ± 110.4 | <0.001* | 495.03 ± 160.1 | 494.13 ± 165.9 | 0.98 | <0.001* |
| ALT, U/L | 44.51 ± 28.1 | 39.85 ± 25.9 | 0.103 | 56.03 ± 35.9 | 57.06 ± 40.2 | 0.954 | 0.489 |
| Albumin, g/dL | 4.03 ± 0.53 | 4.2 ± 0.47 | 0.041* | 4.03 ± 0.58 | 4.23 ± 0.53 | 0.004* | 0.433 |
| Platelets x 103 | 161.4 ± 78.3 | 171.6 ± 84.8 | 0.037* | 145.1 ± 71.9 | 147.6 ± 73.3 | 0.904 | 0.089 |
| PT, sec | 13.23 ± 1.2 | 13.21 ± 1.2 | 0.98 | 13.73 ± 1.7 | 13.65 ± 1.7 | 0.267 | 0.482 |
| INR | 1.1 ± 0.1 | 1.12 ± 0.1 | 0.045* | 1.18 ± 0.2 | 1.16 ± 0.1 | 0.354 | 0.136 |
| Zinc, mcg/dL | 68.47 ± 20.6 | 91.21 ± 28.5 | <0.001* | 68.65 ± 16.6 | 66.25 ± 15.2 | 0.42 | <0.001* |
| Ammonia, µmol/L | 89.1 ± 61.2 | 72.71 ± 27.5 | 0.058 | 95.99 ± 58.1 | 85.54 ± 44.0 | 0.129 | 0.058 |
| CTP score | 5.17 ± 0.5 | 5.03 ± 0.1 | 0.058 | 5.32± 0.6 | 5.19± 0.4 | 0.057 | 0.93 |
| MELD | 9 ± 3.06 | 8.74± 1.7 | 0.561 | 9.15 ± 2.5 | 9.5 ± 2.7 | 0.36 | 0.288 |
Value presented as mean ± SD and n (%) in NP test and laboratory. And presented as median (IQR) in SF-36 test. P-value corresponds to Independent t and Fisher’s exact test. NCT-A, number connection test part A; NCT-B, number connection test part B; DST, digit symbol test; SDT, serial dotting test; LTT, line tracing test; MELD, Model for End-Stage Liver Disease; CTP, Child-Turcotte-Pugh; PF, physical functioning; SF, social functioning; MH, mental health; BP, bodily pain; PH, perception in health; RP, role-physical; RE, role emotional; VT, vitality; P1, Mean change before and after zinc therapy; P2, Mean change before and after placebo; P3, Mean change after therapy compared between group